Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camcevi in Advanced Prostate Cancer
NCT06984159Phase 3Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Nov 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of leuprolide in prostate cancer (PCa), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Jul 2022; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06984159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984159.